Research and Markets: Future Trends in Treatment of Prostate Cancer and Management of Disease and Treatment Side Effects Revealed
Posted on: Thursday, 3 February 2005, 06:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c12474) has announced the addition of Stakeholder Insight: Prostate Cancer Treatment in the USA to their offering.
Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. This Insight details physician opinion of currently available products and disease management practice and what they require in the future.
AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.
Information provided Includes:
-- Quantitative treatment data from 80 physicians from the US
-- Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects
-- Coverage of the hot topics affecting current treatment patterns, from the impact of IMRT on brachytherapy to the increasing use of bisphosphonates
-- A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC
This information will enable readers:
-- Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered
-- Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice
-- Plan product development to fill prostate cancer market niches as defined by practicing physicians
For more information visit http://www.researchandmarkets.com/reports/c12474
Source: Business Wire
Related Articles
- Low Cholesterol May Shrink Risk For High-Grade Prostate Cancer
- Hormone Therapy for Prostate Cancer Patients With Heart Disease May Increase Mortality
- Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
- Wayne State University Scientists ID New Biomarker for Prostate Cancer
- Obesity at the Time of Prostate-Cancer Diagnosis Dramatically Increases the Risk of Dying From the Disease
- Folate May Alter Risk of Prostate Cancer Progression
- Community Care Physicians of Latham, New York Deliver Ultra-Precise Image-Guided Radiotherapy Treatments for Prostate Cancer Patients
- Treatments for Prostate Cancer May Affect Employment
- Dealing With Prostate Cancer
- Richland Firm Introduces Promising Isotope for Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In a Worldwide First for Cesium-131
 |
 |
User Comments (0)
RSS Feeds